The authors declare that the STROBE statement was followed in the article entitled "Establishment of a cholangiocarcinoma risk evaluation model based on mucin expression levels"

STROBE Statement-Checklist of items that should be included in reports of ***cohort studies***

Item No.		**Recommendation**
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Page 1 line 5-6 (b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 3 - Page 4 line 1-9
Introduction		
Background	2	Explain the scientific background and rationale for the investigation being reported Page 5 – Page 6 line 1-7
Objectives	3	State specific objectives, including any prespecified hypotheses Page 6 line 7-13
Methods		
Study design	4	Present key elements of study design early in the paper Page 11 line 10-23
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 10 line 25-27
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Page 10 line 27-28 (b) For matched studies, give matching criteria and number of exposed and unexposed N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 6 line 19
Data sources	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 6 line 17-19
Bias	9	Describe any efforts to address potential sources of bias Page 6 line 19-20
Study size	10	Explain how the study size was arrived at Page 10 line 27-28
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 6 line 21-24
Statistical methods	12	(a) Describe all statistical methods, including those used to control for

		confounding Page 9 line 27-29 – Page 10 line 1-6 (b) Describe any methods used to examine subgroups and interactions Page 6 line 24-27 (c) Explain how missing data were addressed N/a (d) If applicable, explain how loss to follow-up was addressed N/a (e) Describe any sensitivity analyses N/a
Results		
Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Table S1 (b) Give reasons for non-participation at each stage N/a (c) Consider use of a flow diagram N/a
Descriptive data	14	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Table S2 (b) Indicate number of participants with missing data for each variable of interest N/a (c) Summarise follow-up time (eg, average and total amount) N/a
Outcome data	15	Report numbers of outcome events or summary measures over time Page 17 line 8-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Page 12 line 26-28; Page 13 line 15-16; Page 14 line 6-8; Page 15 line 14-16; Page 16 line 26-28; Page 17 line 8-10 (b) Report category boundaries when continuous variables were categorized N/a (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period N/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses N/a
Discussion		
Key results	18	Summarize key results with reference to study objectives

		Page 20 line 18-26
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page 19 line 18-21
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Page 18 line 13-20
Generalisability	21	Discuss the generalisability (external validity) of the study results Page 17 line 23-24
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based N/a